New Products
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
Tenpoint expects to launch its Yuvezzi eye drops in early Q2, where it will compete with other rivals such as LENZ’s Vizz, as well as more traditional options such as glasses and lenses.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company plans to take Aqneursa to regulators in the US, Europe and elsewhere for ataxia-telangiectasia (A-T), which currently lacks any approved therapy.
Two familiar heavyweights of the obesity field return for another match, while four smaller companies are tipped to bring their own blockbusters to market, new data from Evaluate Pharma show.
Just a week after the J.P. Morgan Healthcare conference, GSK’s first buyout of 2026 is focused on anti‑IgE antibody, ozureprubart, which is in Phase II development for prophylactic protection against food allergens.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
CEOs of both the market leaders for weight-loss injections spoke at length during the J.P. Morgan Healthcare conference about the market potential for pills, which are gearing up to become the next frontier in the obesity treatment space.
Upcoming product launches from partnerships with J&J and Takeda could generate billions in royalties for the biotech, which now aims to build an in-house portfolio of next-generation oral obesity drugs and I&I therapies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The firm's type 1 diabetes drug has been given the green light by the European Commission.
The acquisition signals growing belief in the NLRP3 inhibitor class, where companies are increasingly pursuing cardiometabolic and obesity studies alongside neurodegenerative trials.
A deal for the Duchenne muscular dystrophy treatment with Nxera is valued at up to $205m.
Hengrui’s relafupu-α (SHR-1701), a bifunctional fusion protein against PD-L1 and TGF-βR2, has been approved in China in combination with chemotherapy as a first-line treatment for HER2-negative, PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma.
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.
2025 saw star products debut in India as foreign firms doubled down on high-value, IP-protected therapies. Experts tell Scrip the top 10 cities in the country can now sustain “US/EU-style” specialty launches.
With a starter dose price of $149 a month for self-payers, oral Wegovy will be available directly from Novo Nordisk and through telehealth providers and large pharmacy chains.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Catch up on the developments released in the last days of 2025, from year-end FDA approvals, complete response letters and several trial disappointments.
Many new drugs that launched in the US over the last year entered competitive markets and few generated notable revenue in the early months.